Dr. Abdul Qaiyoom Khan - Head, Metabolomics Core
Dr. Abdul Quaiyoom Khan graduated in the year 2013 with a PhD in Toxicology from Jamia Hamdard University in New Delhi, India. He has been awarded various research fellowships from different government funding sources and worked in several research facilities, including the Indian Institute of Genomics and Integrative Biology (IGIB), of the Council of Scientific and Industrial Research in New Delhi, India.
In 2014, he began working as a Research Officer at the Research Center of the Prince Sultan Military Medical City in Riyadh, Saudi Arabia, where he worked on various pre-clinical and clinical research projects. He is currently working as a Post-Doctoral Research Scientist at the Translational Research Institute of Hamad Medical Corporation in Doha, Qatar. In addition, he mentored several graduate and post-graduate students and has worked as the prinicipal investigator and co-principal investigator on various research grants.
He has been working in the field of cancer research for the past twelve years. He has received numerous awards in the field of cancer research throughout this time. His primary research focus is on the molecular mechanisms that underpin cancer pathogenesis and the clinical and therapeutic issues that come with it, such as disease recurrence and drug resistance. He is also passionate about using cutting-edge technologies to discover novel and effective medicines and screening for adverse toxicological symptoms associated with xenobiotic exposure.
Dr. Khan has published more than 60 publications in international peer-reviewed journals and his research insterests include molecular cancer pathogenesis and cancer stem cell research, developmental cancer therapeutics and translational research and drug metabolism and biochemical toxicology.
Select Publications:
Khan AQ, Al-Tamimi M, Uddin S, Steinhoff M. F-box proteins in cancer stemness: An emerging prognostic and therapeutic target. Drug Discov Today. 2021 Jul 12:S1359-6446(21)00314-7.
Khan AQ, Rashid K, AlAmodi AA, Agha MV, Akhtar S, Hakeem I, Raza SS, Uddin S. Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomed Pharmacother. 2021 Nov;143:112142.
Khan AQ, Ahmed EI, Elareer N, Fathima H, Prabhu KS, Siveen KS, Kulinski M, Azizi F, Dermime S, Ahmad A, Steinhoff M, Uddin S. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway. Int J Mol Sci. 2020 Jan 9;21(2):438.
Khan AQ, Ahmad F, Raza SS, Zarif L, Siveen KS, Sher G, Agha MV, Rashid K, Kulinski M, Buddenkotte J, Uddin S, Steinhoff M. Role of non-coding RNAs in the progression and resistance of cutaneous malignancies and autoimmune diseases. Semin Cancer Biol. 2020 Jul 25: S1044-579X(20)30158-9.
Khan AQ, Mohamed EAN, Hakeem I, Nazeer A, Kuttikrishnan S, Prabhu KS, Siveen KS, Nawaz Z, Ahmad A, Zayed H, Uddin S. Sanguinarine Induces Apoptosis in Papillary Thyroid Cancer Cells via Generation of Reactive Oxygen Species. Molecules. 2020 Mar 9;25(5):1229.
